How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease · Investor's Business Daily
ALLISON GATLIN
2 min read

In This Article:

Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.

Recommended Stories